Clinical trial · Interventional
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer
PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER
NCT02206724CI-TRIAL-00032600withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Unable to enroll patients
Summary
Brief summary (as posted)
The investigators aim to test the safety and feasibility of prostate gland stereotactic body radiotherapy (SBRT) plus best systemic therapy in newly diagnosed metastatic prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STEREOTACTIC BODY RADIOTHERAPY to the prostate gland | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- STEREOTACTIC BODY RADIOTHERAPY
- description
- STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
- interventionNames
- Radiation: STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
Primary outcomes (1)
- measure
- Radiation related toxicity
- timeFrame
- 5 years
- description
- Radiation related toxicity as per history and physical, and 1 or several of Patient questionnaires: SF-12 questionnaire AUA questionnaire EPIC-26 questionnaire SHIM questionnaire Utilization of Sexual Medications/Devices questionnaire
Secondary outcomes (1)
- measure
- Feasibility
- timeFrame
- 3-4 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically-confirmed, adenocarcinoma of the prostate * Clinical Stage T1b - T4, NX-0-1, M1 * Any Gleason score * PSA\<1000 * ECOG Performance Status 0-2 * No prior prostate radiation or other definitive therapy Exclusion Criteria: * Prior prostatectomy or cryotherapy of the prostate * Prior radiotherapy to the prostate or lower pelvis * Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion * Chemotherapy for a malignancy in the last 5 years * History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.